Composite application of high purified and recombinant human bone morphogenetic protein to the biomaterials.

1.重组人骨形态发生蛋白-2（rhBMP-2）在肌肉部位、皮下部位、骨骼部位和联合皮瓣部位均表现出稳定的骨诱导活性，而纯化的BMP（pBMP）诱导的骨基质丰富，其诱导活性约为相同剂量rhBMP-2.2的10倍。将10μ grhBMP-2和I型胶原冻干多孔羟基磷灰石片植入兔下颌骨颊侧骨缺损区。在植入后21天，骨小梁内衬孔壁。在中央部分，观察到包括血管样组织的骨髓。将冻干的钛种植体和10μg rhBMP-2和I型胶原（n=6）放置在狗下颌骨中。植入后12周，螺纹之间显示骨形成。BMP刺激的植入物表面的骨接触百分比高。在抗扭转强度方面，含pBMP的钛种植体在短时间内获得了较高的结合强度，提示含BMP的多孔羟基磷灰石可作为骨缺损修复的支架材料。钛种植体与骨形态发生蛋白的联合使用有可能缩短从固定植入手术到基台连接手术所需的时间.将2 μg rhBMP-2和不同量的重组人碱性生长因子（bFGF; 0、16、80、400 ng和2、10、50μg）混合并植入大鼠小腿肌肉中。植入3周后，rhBMP-2的成骨活性随着bFGF浓度的增加而增强，随着bFGF浓度的增加而减弱。这些结果表明，与bFGF的伴随治疗显示双相效应的rhBMP-2的骨诱导活性。

1. Recombinant human bone morphogenetic protein-2 (rhBMP-2) indicated stable osteoinduction at muscle sites, subcutaneous sites, skeletal sites, and combined flap sites, however, purified BMP (pBMP) induces rich bone matrix and indicated about tenfold of osteoinducing activity than same dose of rhBMP-2.2. The lyophilized porous hydroxyapatite disk with 10μg of rhBMP-2 and type I collagen (n=15) were implanted into the surgically created bone defect of the buccal side on the rabbit mandible. At 21 days after implantation, trabecular bone lined pore walls. In the central portion, the bone marrow including angioid tissue was observed. New trabecular bone formation was observed on portions of the external surface of the porous hydroxyapatite disk.The lyophilized titanium implants and 10μg of rhBMP-2 and type I collagen (n=6) were placed in dog mandibles. At 12 weeks after implantation, Bone formation was shown between the threads. High percentage of bone contact at the BMP stimulated implant surfaces was indicated. In the reverse torque strength, titanium implants with pBMP obtains high bond strength within a short time period.These results suggests that porous hydroxyapatite with BMP is useful as a framing materials for reconstruction of widespread bone defects. The use of the titanium implants with BMP has the possibility of shortening the time required between fixture implantation surgery and abutment connection surgery.3. Two μg of rhBMP-2 and different amounts of recombinant human basic growth factor (bFGF; 0, 16, 80, and 400ng, and 2, 10, and 50μg) were mixed and implanted into rat calf muscles. Three weeks after implantation, rhBMP-2 increased osteoinducing activity with low dose of bFGF and decreased with high dose bFGF. These results suggests that concomitant treatment with bFGF shows biphasic effects to the osteoinducing activity by rhBMP-2.